罗红霉素维持治疗稳定期COPD的探讨

The Clinical Research of Long-term Treatment with Roxithromycin in Stable Chronic Obstructive Pulmonary Disease

目的:探讨罗红霉素缓释胶囊维持治疗稳定期慢性阻塞性肺疾病(COPD)的疗效。方法:选择113例稳定期慢性阻塞性肺疾病患者,按照随机数字表法分为治疗组和对照组,两组均给予常规的氧疗、化痰、平喘、调节免疫、支持及健康教育等治疗。在此基础上,治疗组予以罗红霉素缓释胶囊0.15 g,口服,1次/d,维持治疗6个月。治疗结束后对比组内治疗前后患者呼吸困难、肺功能、6 min步行试验(6-MWT)、生活质量、急性加重次数指标,并对治疗后两组上述指标进行对比分析。结果:两组自身治疗前后对比,治疗后FEV1/FVC(%)及6-MWT均较治疗前增加,急性发作频率及呼吸困难情况均较治疗前减少,生活质量提高(P<0.05);治疗组治疗后FEV1/FVC(%)及6-MWT高于对照组,急性发作频率及呼吸困难程度低于对照组,生活质量评估优于对照组,差异均有统计学意义(P<0.05)。结论:罗红霉素缓释胶囊维持治疗稳定期COPD对缓解呼吸困难、改善肺功能、提高生活质量及预防复发疗效显著。

Objective：To study the efficacy of Roxithromycin Sustained Release Capsulesin（RSRC） in treating stable Chronic Obstructive Pulmonary Disease（COPD） patients.Method：Totally 113 patients with stable COPD were randomly divided into the treatment group and the control group. All the patients were treated with basic therapy（including oxygen,eliminating phlegm to smooth wheezing,immune regulation,support treatment and health education）.The treatment group in the basic therapy combined with RSRC 0.15 g,1/d oral for 6 months.Dyspnea score,pulmonary function（FEV1/FVC）,6-MWT,the quality of life（QOL） and the times of exacerbations were observed.Result：The indicators of FEV1/FVC（%）,6-MWT and QOL were higher than those before the treatment（P〈0.05）.The times of exacerbations and dyspnea score were smaller than those before the treatment（P〈0.05）.The indicators of FEV1/FVC（%）,6-MWT and QOL in the treatment group were higher than those in the control group after the treatment（P〈0.05）.The times of exacerbations and dyspnea score in the treatment group were smaller than those in the control group after the treatment （P〈0.05）.Conclusion：Long-term treatment for stable COPD patients with RSRC is an effective means in relieving dyspnea,improving pulmonary function and QOL and preventing recurrence.